Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

No specific studies are available however based on physicochemical data, toxicity data and theoretical assessment, the basic toxicokinetics of Fatty acids C18 unsat, reaction products with pentaethylenehexamine, acetate salts can be adequately characterised. No absorption of the intact substance via the oral, dermal or inhalation routes is predicted. Consideration of distribution, metabolism and excretion is not therefore relevant. In the absence of systemic bioavailability, bioaccumulation is not predicted. 

Key value for chemical safety assessment

Bioaccumulation potential:
no bioaccumulation potential

Additional information

No specific studies are required. According to Column 1 of Annex VIII of the REACH regulation, assessment of the toxicokinetic behaviour of the substance (to the extent that can be derived from the relevant available information) is required and this is provided. An adequate assessment of the basic toxicokinetics of the substance can be made from the existing toxicity data and theoretical considerations, without the need for specific testing.


Oral absorption of the substance is not predicted according to Lipinski’s Rule (OECD QSAR Toolbox v3.1: OASIS); this is likely to be due to the high molecular weight of the substance. Toxicity data on the substance are limited to a study of acute oral toxicity; this study reported mortality in one group administered 2000 mg/kg bw and non-specific signs of toxicity at 300 mg/kg bw.

While oral absorption of the intact substance is not predicted, it is possible that hydrolysis of the substance in the gastrointestinal tract may result in the liberation of low molecular weight hydrolysis products which may be bioavailable and which may be able to exert toxicity. However the substance is predicted to be hydrolytically stable (including at gastrointestinal tract pH), therefore this is considered to be unlikely.

No data on dermal absorption are available; however based on the predicted absence of oral absorption, dermal absorption is similarly not predicted.

No data on inhalation absorption are available; however absorption is dependent on inhalation exposure which is not predicted based on the physicochemical properties (i.e. low vapour pressure and high boiling point) and the use pattern of the substance.

Oral absorption of the substance is not predicted. Nevertheless, for the purposes of risk assessment, the level of oral and dermal absorption are considered to be equivalent (default, worst-case assumption) and the extent of inhalation absorption is considered to be twice that of oral absorption (default assumption).


Absorption of the intact substance or hydrolysis products is not predicted; therefore consideration of distribution is not relevant.


Absorption of the intact substance or hydrolysis products is not predicted; therefore consideration of metabolism is not directly relevant. However the OECD QSAR Toolbox predicts metabolism (by rat liver S9 fraction) through hydrolysis at the terminal amine group (with the liberation of acetic acid), at the central amide group or at the non-terminal secondary amine groups. The differential response of bacterial strains to the substance in the presence and absence of metabolic activation indicates a reduction of toxicity by metabolic enzymes.


Absorption of the intact substance or hydrolysis products is not predicted; therefore consideration of excretion is not relevant.